WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-06-18·Latest →

Bristol Myers Squibb (BMY) Stock Analysis

OW

BMY Equity Research — OVERWEIGHT — June 2026

← AMGNCVS →

Rating date

Jun 18, 2026

53 days ago

Desk view

OW

5D move

—

Awaiting market data

Peer rank

38p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · BMY

Here is the analysis note.

Desk rating

OW

Tactical OW · 12M OW

Horizon

Long-term

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

OVERWEIGHT

Catalysts

  • BMY enjoyed a strong ~24% gain over the past 12 months, but the recent pullback from the $60–$61 zone is technically concerning.
  • RSI (43.1) and MACD (-0.44) both point to deteriorating short-term momentum — the MACD has re-widened negatively after a failed crossover attempt.
  • The lower high at $60.25 (May 22 vs. Apr 1 high of $61.10) and the series of lower closes since Jun 12 ($57.13 → $56.24 → $55.92 → $55.28) form a bearish short-term structure.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

BMY Research Note

Full desk note for Jun 18, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

27 min read

WebserviceX · Agentic Research Desk

BMY Equity Research Note

Published Jun 18, 2026 · Desk view OVERWEIGHT · Generated 2026-06-19T07:40:28Z · Maintained by Walter Vijayakumar · Methodology · Track record

BMY Stock Rating Summary

BMY bias

OVERWEIGHT

Horizon

Long-term

BMY key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

BMY catalyst watch

BMY enjoyed a strong ~24% gain over the past 12 months, but the recent pullback from the $60–$61 zone is technically concerning.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

—Awaiting market dataPeer 38p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-06-19T08:42:26.778477+00:00.

5D move

—

2026-06-17 → awaiting

Outcome

Awaiting market data

5D trend

-0.58%

Vol (20D ann.)

+28.14%

vs SPY: -2.72%

Close 55.28 → — (USD, vendor closes)

Batch scorecard · 2026-06-18 · BMY

Publish QC

passed
Expand

Pipeline fingerprint 2f45a102687f75c0

Trace eff56581…

No QC issues recorded.